Literature DB >> 28352651

Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea.

Marie-Astrid Vernet1, Stéphanie Reynard2,3, Alexandra Fizet2,3, Justine Schaeffer2,3, Delphine Pannetier4, Jeremie Guedj5,6, Max Rives7, Nadia Georges7, Nathalie Garcia-Bonnet7, Aboubacar I Sylla8, Péma Grovogui8, Jean-Yves Kerherve7, Christophe Savio7, Sylvie Savio-Coste7, Marie-Laure de Séverac7, Philippe Zloczewski7, Sandrine Linares7, Souley Harouna9, Bing M'Lebing Abdoul9, Frederic Petitjean9, Nenefing Samake9, Susan Shepherd9, Moumouni Kinda9, Fara Roger Koundouno9, Ludovic Joxe9, Mathieu Mateo2,3, Patrick Lecine10, Audrey Page2,3, Tang Maleki Tchamdja7, Matthieu Schoenhals1, Solenne Barbe9, Bernard Simon11, Tuan Tran-Minh11, Christophe Longuet12, François L'Hériteau13, Sylvain Baize2,3.   

Abstract

BACKGROUND. The pathogenesis of Ebola virus (EBOV) disease (EVD) is poorly characterized. The establishment of well-equipped diagnostic laboratories close to Ebola treatment centers (ETCs) has made it possible to obtain relevant virological and biological data during the course of EVD and to assess their association with the clinical course and different outcomes of the disease. METHODS. We were responsible for diagnosing EBOV infection in patients admitted to two ETCs in forested areas of Guinea. The pattern of clinical signs was recorded, and an etiological diagnosis was established by RT-PCR for EBOV infection or a rapid test for malaria and typhoid fever. Biochemical analyses were also performed. RESULTS. We handled samples from 168 patients between November 29, 2014, and January 31, 2015; 97 patients were found to be infected with EBOV, with Plasmodium falciparum coinfection in 18%. Overall mortality for EVD cases was 58%, rising to 86% if P. falciparum was also present. Viral load was higher in fatal cases of EVD than in survivors, and fatal cases were associated with higher aspartate aminotransferase (AST) and alanine aminotransferase (ALT), C-reactive protein (CRP), and IL-6 levels. Furthermore, regardless of outcome, EVD was characterized by higher creatine kinase (CPK), amylase, and creatinine levels than in febrile patients without EVD, with higher blood urea nitrogen (BUN) levels in fatal cases of EVD only. CONCLUSION. These findings suggest that a high viral load at admission is a marker of poor EVD prognosis. In addition, high AST, ALT, CRP, and IL-6 levels are associated with a fatal outcome of EVD. Damage to the liver and other tissues, with massive rhabdomyolysis and, probably, acute pancreatitis, is associated with EVD and correlated with disease severity. Finally, biochemical analyses provide substantial added value at ETCs, making it possible to improve supportive rehydration and symptomatic care for patients. FUNDING. The French Ministry of Foreign Affairs, the Agence Française de Développement, and Institut Pasteur.

Entities:  

Mesh:

Year:  2017        PMID: 28352651      PMCID: PMC5358491          DOI: 10.1172/jci.insight.88864

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  39 in total

Review 1.  Ebola virus in West Africa: new conquered territories and new risks-or how I learned to stop worrying and (not) love Ebola virus.

Authors:  Sylvain Baize
Journal:  Curr Opin Virol       Date:  2015-02-06       Impact factor: 7.090

2.  IL-6 increases endothelial permeability in vitro.

Authors:  N Maruo; I Morita; M Shirao; S Murota
Journal:  Endocrinology       Date:  1992-08       Impact factor: 4.736

3.  Human asymptomatic Ebola infection and strong inflammatory response.

Authors:  E M Leroy; S Baize; V E Volchkov; S P Fisher-Hoch; M C Georges-Courbot; J Lansoud-Soukate; M Capron; P Debré; J B McCormick; A J Georges
Journal:  Lancet       Date:  2000-06-24       Impact factor: 79.321

4.  Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection.

Authors:  F Villinger; P E Rollin; S S Brar; N F Chikkala; J Winter; J B Sundstrom; S R Zaki; R Swanepoel; A A Ansari; C J Peters
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

Review 5.  The syndrome of rhabdomyolysis: complications and treatment.

Authors:  Yiannis S Chatzizisis; Gesthimani Misirli; Apostolos I Hatzitolios; George D Giannoglou
Journal:  Eur J Intern Med       Date:  2008-04-28       Impact factor: 4.487

6.  Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease.

Authors:  Etienne Gignoux; Andrew S Azman; Martin de Smet; Philippe Azuma; Moses Massaquoi; Dorian Job; Amanda Tiffany; Roberta Petrucci; Esther Sterk; Julien Potet; Motoi Suzuki; Andreas Kurth; Angela Cannas; Anne Bocquin; Thomas Strecker; Christopher Logue; Thomas Pottage; Constanze Yue; Jean-Clement Cabrol; Micaela Serafini; Iza Ciglenecki
Journal:  N Engl J Med       Date:  2016-01-07       Impact factor: 91.245

7.  Rhabdomyolysis in Ebola Virus Disease. Results of an Observational Study in a Treatment Center in Guinea.

Authors:  Jean Marie Cournac; Ludovic Karkowski; Julien Bordes; Marc Aletti; Sandrine Duron; Frédéric Janvier; Vincent Foissaud; Hélène Savini; Thierry de Greslan; Claire Rousseau; Magali Billhot; Nicolas Gagnon; Christine Mac Nab; Philippe Dubrous; Sophie Moroge; Helene Broto; Jean Cotte; Nancy Maugey; Pierre-Yves Cordier; Emmanuel Sagui; Audrey Merens; Christophe Rapp; Benoit Quentin; Hervé Granier; Thierry Carmoi; Gilles Cellarier
Journal:  Clin Infect Dis       Date:  2015-09-03       Impact factor: 9.079

8.  Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus.

Authors:  Pierre E Rollin; Daniel G Bausch; Anthony Sanchez
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

9.  Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Final Report.

Authors:  Gibrilla F Deen; Nathalie Broutet; Wenbo Xu; Barbara Knust; Foday R Sesay; Suzanna L R McDonald; Elizabeth Ervin; Jaclyn E Marrinan; Philippe Gaillard; Ndema Habib; Hongtu Liu; William Liu; Anna E Thorson; Francis Yamba; Thomas A Massaquoi; Faustin James; Archchun Ariyarajah; Christine Ross; Kyle Bernstein; Antoine Coursier; John Klena; Marylin Carino; Alie H Wurie; Yong Zhang; Marion S Dumbuya; Neetu Abad; Baimba Idriss; Teodora Wi; Sarah D Bennett; Tina Davies; Faiqa K Ebrahim; Elissa Meites; Dhamari Naidoo; Samuel J Smith; Patricia Ongpin; Tasneem Malik; Anshu Banerjee; Bobbie R Erickson; Yongjian Liu; Yang Liu; Ke Xu; Aaron Brault; Kara N Durski; Jörn Winter; Tara Sealy; Stuart T Nichol; Margaret Lamunu; James Bangura; Sihem Landoulsi; Amara Jambai; Oliver Morgan; Guizhen Wu; Mifang Liang; Qiudong Su; Yu Lan; Yanzhe Hao; Pierre Formenty; Ute Ströher; Foday Sahr
Journal:  N Engl J Med       Date:  2015-10-14       Impact factor: 91.245

10.  Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Authors:  Daouda Sissoko; Cedric Laouenan; Elin Folkesson; Abdoul-Bing M'Lebing; Abdoul-Habib Beavogui; Sylvain Baize; Alseny-Modet Camara; Piet Maes; Susan Shepherd; Christine Danel; Sara Carazo; Mamoudou N Conde; Jean-Luc Gala; Géraldine Colin; Hélène Savini; Joseph Akoi Bore; Frederic Le Marcis; Fara Raymond Koundouno; Frédéric Petitjean; Marie-Claire Lamah; Sandra Diederich; Alexis Tounkara; Geertrui Poelart; Emmanuel Berbain; Jean-Michel Dindart; Sophie Duraffour; Annabelle Lefevre; Tamba Leno; Olivier Peyrouset; Léonid Irenge; N'Famara Bangoura; Romain Palich; Julia Hinzmann; Annette Kraus; Thierno Sadou Barry; Sakoba Berette; André Bongono; Mohamed Seto Camara; Valérie Chanfreau Munoz; Lanciné Doumbouya; Patient Mumbere Kighoma; Fara Roger Koundouno; Cécé Moriba Loua; Vincent Massala; Kinda Moumouni; Célia Provost; Nenefing Samake; Conde Sekou; Abdoulaye Soumah; Isabelle Arnould; Michel Saa Komano; Lina Gustin; Carlotta Berutto; Diarra Camara; Fodé Saydou Camara; Joliene Colpaert; Léontine Delamou; Lena Jansson; Etienne Kourouma; Maurice Loua; Kristian Malme; Emma Manfrin; André Maomou; Adele Milinouno; Sien Ombelet; Aboubacar Youla Sidiboun; Isabelle Verreckt; Pauline Yombouno; Anne Bocquin; Caroline Carbonnelle; Thierry Carmoi; Pierre Frange; Stéphane Mely; Vinh-Kim Nguyen; Delphine Pannetier; Anne-Marie Taburet; Jean-Marc Treluyer; Jacques Kolie; Raoul Moh; Minerva Cervantes Gonzalez; Eeva Kuisma; Britta Liedigk; Didier Ngabo; Martin Rudolf; Ruth Thom; Romy Kerber; Martin Gabriel; Antonino Di Caro; Roman Wölfel; Jamal Badir; Mostafa Bentahir; Yann Deccache; Catherine Dumont; Jean-François Durant; Karim El Bakkouri; Marie Gasasira Uwamahoro; Benjamin Smits; Nora Toufik; Stéphane Van Cauwenberghe; Khaled Ezzedine; Eric D'Ortenzio; Eric Dortenzio; Louis Pizarro; Aurélie Etienne; Jérémie Guedj; Alexandra Fizet; Eric Barte de Sainte Fare; Bernadette Murgue; Tuan Tran-Minh; Christophe Rapp; Pascal Piguet; Marc Poncin; Bertrand Draguez; Thierry Allaford Duverger; Solenne Barbe; Guillaume Baret; Isabelle Defourny; Miles Carroll; Hervé Raoul; Augustin Augier; Serge P Eholie; Yazdan Yazdanpanah; Claire Levy-Marchal; Annick Antierrens; Michel Van Herp; Stephan Günther; Xavier de Lamballerie; Sakoba Keïta; France Mentre; Xavier Anglaret; Denis Malvy
Journal:  PLoS Med       Date:  2016-03-01       Impact factor: 11.069

View more
  31 in total

1.  T-Cell Receptor Diversity and the Control of T-Cell Homeostasis Mark Ebola Virus Disease Survival in Humans.

Authors:  Emily Speranza; Paula Ruibal; Julia R Port; Feng Feng; Lia Burkhardt; Adam Grundhoff; Stephan Günther; Lisa Oestereich; Julian A Hiscox; John H Connor; César Muñoz-Fontela
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

2.  The Effect of Plasmodium on the Outcome of Ebola Virus Infection in a Mouse Model.

Authors:  Kyle Rosenke; Reinaldo Mercado-Hernandez; Jacqueline Cronin; Solomon Conteh; Patrick Duffy; Heinz Feldmann; Emmie de Wit
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

3.  A drug-disease model for predicting survival in an Ebola outbreak.

Authors:  Masood Khaksar Toroghi; Nidal Al-Huniti; John D Davis; A Thomas DiCioccio; Ronda Rippley; Alina Baum; Christos A Kyratsous; Sumathi Sivapalasingam; Joel Kantrowitz; Mohamed A Kamal
Journal:  Clin Transl Sci       Date:  2022-08-17       Impact factor: 4.438

Review 4.  The kidney in hantavirus infection-epidemiology, virology, pathophysiology, clinical presentation, diagnosis and management.

Authors:  Felix C Koehler; Veronica Di Cristanziano; Martin R Späth; K Johanna R Hoyer-Allo; Manuel Wanken; Roman-Ulrich Müller; Volker Burst
Journal:  Clin Kidney J       Date:  2022-01-29

5.  Role of Transmembrane Protein 16F in the Incorporation of Phosphatidylserine Into Budding Ebola Virus Virions.

Authors:  Patrick Younan; Mathieu Iampietro; Rodrigo I Santos; Palaniappan Ramanathan; Vsevolod L Popov; Alexander Bukreyev
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

Review 6.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

7.  Acute Plasmodium Infection Promotes Interferon-Gamma-Dependent Resistance to Ebola Virus Infection.

Authors:  Kai J Rogers; Olena Shtanko; Rahul Vijay; Laura N Mallinger; Chester J Joyner; Mary R Galinski; Noah S Butler; Wendy Maury
Journal:  Cell Rep       Date:  2020-03-24       Impact factor: 9.423

8.  The impact of malaria coinfection on Ebola virus disease outcomes: A systematic review and meta-analysis.

Authors:  Hannah M Edwards; Helen Counihan; Craig Bonnington; Jane Achan; Prudence Hamade; James K Tibenderana
Journal:  PLoS One       Date:  2021-05-24       Impact factor: 3.240

Review 9.  Host Transcriptional Response to Ebola Virus Infection.

Authors:  Emily Speranza; John H Connor
Journal:  Vaccines (Basel)       Date:  2017-09-20

Review 10.  Ebola virus disease.

Authors:  Shevin T Jacob; Ian Crozier; William A Fischer; Angela Hewlett; Colleen S Kraft; Marc-Antoine de La Vega; Moses J Soka; Victoria Wahl; Anthony Griffiths; Laura Bollinger; Jens H Kuhn
Journal:  Nat Rev Dis Primers       Date:  2020-02-20       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.